| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Kininogen1 |
| Uniprot No | P01042-2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-380aa |
| 氨基酸序列 | MASMTGGQQMGRGHHHHHHGNLYFQGGEFQESQSEEIDCNDKDLFKAVDA ALKKYNSQNQSNNQFVLYRITEATKTVGSDTFYSFKYEIKEGDCPVQSGK TWQDCEYKDAAKAATGECTATVGKRSSTKFSVATQTCQITPAEGPVVTAQ YDCLGCVHPISTQSPDLEPILRHGIQYFNNNTQHSSLFMLNEVKRAQRQV VAGLNFRMTYSIVQTNCSKENFLFLTPDCKSLWNGDTGECTDNAYIDIQL RIASFSQNCDIYPGKDFVQPPTKICVGCPRDIPTNSPELEETLTHTITKL NAENNATFYFKIDNVKKARVQVVAGKKYFIDFVARETTCSKESNEELTES CETKKLGQSLDCNAEVYVVPWEKKIYPTVNCQPLGMISLMK |
| 预测分子量 | 48 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于Kininogen1重组蛋白的模拟参考文献示例，涵盖表达、功能及结构研究：
---
1. **"Recombinant production and characterization of human high-molecular-weight kininogen in mammalian cells"**
*Authors: Smith J, Lee R, et al.*
**摘要**：本研究利用HEK293细胞成功表达并纯化重组人高分子量激肽原(HMWK)，证实其具备与天然蛋白相似的糖基化修饰和功能活性，为后续生化研究提供可靠工具。
2. **"Role of recombinant kininogen1 in modulating inflammation and coagulation pathways in vitro"**
*Authors: Tanaka M, Zhang Y, et al.*
**摘要**：通过体外实验发现，重组Kininogen1可抑制缓激肽释放，并调节凝血因子XII的活化，提示其在治疗血栓及炎症性疾病中的潜在应用。
3. **"Crystal structure of recombinant kininogen1 domain 3 reveals key binding motifs for kallikrein interaction"**
*Authors: Garcia S, Müller T, et al.*
**摘要**：首次解析重组Kininogen1第3结构域的晶体结构，阐明其与激肽释放酶结合的分子机制，为靶向药物设计提供结构基础。
4. **"Therapeutic potential of recombinant kininogen1 in a murine sepsis model"**
*Authors: Chen L, Park H, et al.*
**摘要**：在小鼠败血症模型中，重组Kininogen1显著降低炎症因子水平并改善生存率，提示其作为新型抗炎治疗策略的可能性。
---
注：以上文献为示例性内容，实际研究中建议通过PubMed或Web of Science检索真实文献。
**Background of Recombinant Kininogen 1 Protein**
Kininogen 1 (KNG1), a member of the kininogen family, is a multifunctional glycoprotein encoded by the *KNG1* gene in humans. It exists in two primary isoforms: high-molecular-weight kininogen (HMWK) and low-molecular-weight kininogen (LMWK), generated via alternative splicing. HMWK plays a critical role in the contact activation system, bridging coagulation, inflammation, and innate immunity, while LMWK is primarily involved in regulating vascular permeability and cellular interactions.
KNG1 serves as a precursor for bradykinin, a potent vasoactive peptide released through proteolytic cleavage by kallikreins. Bradykinin mediates physiological processes such as blood pressure regulation, pain signaling, and inflammatory responses. Structurally, KNG1 contains multiple domains, including a histidine-rich region, cysteine protease inhibitory motifs, and binding sites for platelets, neutrophils, and endothelial cells. Its ability to interact with proteases (e.g., kallikrein) and inhibitors (e.g., cystatin) underscores its dual role in promoting and modulating coagulation and inflammation.
Recombinant KNG1 protein is produced using expression systems (e.g., mammalian or insect cells) to ensure proper post-translational modifications, such as glycosylation and disulfide bond formation. This engineered protein retains the functional properties of native KNG1. enabling studies on its biochemical interactions, receptor binding, and involvement in pathological conditions like hereditary angioedema, thrombosis, and sepsis.
Research applications include elucidating KNG1's role in the kallikrein-kinin system (KKS), developing therapeutic agents targeting bradykinin pathways, and exploring its diagnostic potential as a biomarker. Recombinant KNG1 also aids in standardizing assays for coagulation disorders and validating drug candidates aimed at modulating inflammatory or thrombotic diseases. Its study provides insights into the delicate balance between pro- and anti-coagulant mechanisms, offering avenues for novel treatments in cardiovascular and immune-related disorders.
×
